<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01193218</url>
  </required_header>
  <id_info>
    <org_study_id>1245.38</org_study_id>
    <nct_id>NCT01193218</nct_id>
  </id_info>
  <brief_title>Empagliflozin (BI 10773) Dose Finder Study in Japanese Patients With Type 2 Diabetes Mellitus</brief_title>
  <official_title>A Double-blind, Randomised, Parallel Group Efficacy and Safety Study of BI 10773 (5 mg, 10 mg, 25 mg, and 50 mg) Compared to Placebo When Administered Orally Once Daily Over 12 Weeks, as Monotherapy, in Patients With Type 2 Diabetes and Insufficient Glycaemic Control Despite Diet and Exercise, Followed by a 40 Week Randomised Extension Study to Assess Long Term Safety of BI 10773 (10 mg and 25 mg)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      This study is conducted to determine the most appropriate therapeutic doses of BI 10773 in
      Japanese patients with T2DM at first treatment period. The second treatment period is
      required to obtain sufficient safety data (one-year exposure to BI 10773) in Japanese
      patients with T2DM according to the ICH E1 guideline.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in HbA1c After 12 Weeks of Treatment.</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>The primary endpoint in this study is the change from baseline in HbA1c after 12 weeks of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Treat to Target Efficacy Response</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>Occurrence of treat to target efficacy response, that is an HbA1c of &lt;7.0% after 12 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in FPG</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>Change from baseline in FPG after 12 weeks of treatment</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Confirmed Hypoglycaemic Adverse Events</measure>
    <time_frame>between first drug intake of study medication up to a period of 7 days (inclusive) after the last drug intake of study medication, up to 392 days</time_frame>
    <description>Number of patients with confirmed hypoglycaemic adverse events</description>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">547</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>BI 10773 low dose QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BI 10773 tablets low dose once a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 10773 mid-low dose QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BI 10773 tablets mid-low dose once a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 10773 mid-high dose QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BI 10773 tablets mid-high dose once a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 10773 high dose QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BI 10773 tablets high dose once a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablets once a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (low dose)</intervention_name>
    <description>Placebo tablets once a day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (low dose)</intervention_name>
    <description>Placebo tablets once a day</description>
    <arm_group_label>BI 10773 high dose QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (mid dose)</intervention_name>
    <description>Placebo tablets once a day</description>
    <arm_group_label>BI 10773 low dose QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (high dose)</intervention_name>
    <description>Placebo tablets once a day</description>
    <arm_group_label>BI 10773 low dose QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773</intervention_name>
    <description>BI 10773 tablets low dose once a day</description>
    <arm_group_label>BI 10773 low dose QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (mid dose)</intervention_name>
    <description>Placebo tablets once a day</description>
    <arm_group_label>BI 10773 high dose QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (high dose)</intervention_name>
    <description>Placebo tablets once a day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (high dose)</intervention_name>
    <description>Placebo tablets once a day</description>
    <arm_group_label>BI 10773 mid-low dose QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773</intervention_name>
    <description>BI 10773 tablets mid-high dose once a day</description>
    <arm_group_label>BI 10773 mid-high dose QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773</intervention_name>
    <description>BI 10773 tablets high dose once a day</description>
    <arm_group_label>BI 10773 high dose QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (mid dose)</intervention_name>
    <description>Placebo tablets once a day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (high dose)</intervention_name>
    <description>Placebo tablets once a day</description>
    <arm_group_label>BI 10773 mid-high dose QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (low dose)</intervention_name>
    <description>Placebo tablets once a day</description>
    <arm_group_label>BI 10773 mid-low dose QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (low dose)</intervention_name>
    <description>Placebo tablets once a day</description>
    <arm_group_label>BI 10773 mid-high dose QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773</intervention_name>
    <description>BI 10773 tablets mid-low dose once a day</description>
    <arm_group_label>BI 10773 mid-low dose QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (mid dose)</intervention_name>
    <description>Placebo tablets once a day</description>
    <arm_group_label>BI 10773 mid-high dose QD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Diagnosis of type 2 diabetes mellitus prior to informed consent

          -  Male and female patients on diet and exercise regimen who are:

               1. drug-naïve, defined as no antidiabetic drugs for 10 weeks prior to informed
                  consent.

               2. pre-treated with one oral antidiabetic drug; the present antidiabetic therapy has
                  to be unchanged for 10 weeks prior to informed consent.

          -  HbA1c at Visit 1a:

               1. for patients who are drug naïve: HbA1c &gt;=7.0 to =&lt;10.0%

               2. for patients treated with one oral antidiabetic drug: HbA1c &gt;=6.5 to =&lt;9.0%

          -  HbA1c of &gt;=7.0% and =&lt;10% at Visit 2 (start of run-in)

        Exclusion criteria:

          -  Uncontrolled hyperglycaemia with a glucose level &gt;240 mg/dL (&gt;13.3 mmol/L) after an
             overnight fast during wash-out/placebo run-in period and confirmed by a second
             measurement (not on the same day).

          -  Acute coronary syndromes, stroke or transient ischaemic attack within 12 weeks prior
             to informed consent

          -  Impaired renal function, defined as calculated eGFR &lt;60 ml/min (MDRD formula) during
             screening and/or wash-out period and/or run-in phase.

          -  Bariatric surgery within the past 2 years and other gastrointestinal surgeries that
             induce chronic malabsorption

          -  Blood dyscrasias or any disorders causing hemolysis or unstable Red Blood Cell (e.g.
             malaria, babesiosis, haemolytic anemia)

          -  Treatment with anti-obesity drugs (e.g. sibutramine, mazindol) 12 weeks prior to
             informed consent or any other treatment at the time of screening (i.e. surgery,
             aggressive diet regimen, etc.) leading to unstable body weight
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1245.38.016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chiyoda-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.38.001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chuo-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.38.003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chuo-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.38.002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hachioji, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.38.010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hanamaki, Iwate</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.38.005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kamakura, Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.38.020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kanazawa, Ishikawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.38.013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kashiwa, Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.38.019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Katsushika-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.38.021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kyoto, Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.38.024 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Matsuyama, Ehime</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.38.004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Minato-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.38.011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moriya, Ibaraki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.38.030 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Naha, Okinawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.38.032 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Okawa, Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.38.031 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Okinawa, Okinawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.38.025 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saga, Saga</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.38.014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saitama, Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.38.006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sapporo, Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.38.007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sapporo, Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.38.008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sapporo, Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.38.009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sapporo, Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.38.012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sasima-gun, Ibaraki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.38.015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shinjuku-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.38.018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shinjuku-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.38.017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Suginami-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.38.022 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Suita, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.38.023 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ube, Yamaguchi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.38.026 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Urasoe, Okinawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.38.027 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Urasoe, Okinawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.38.028 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Urasoe, Okinawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.38.029 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Urasoe, Okinawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2010</study_first_submitted>
  <study_first_submitted_qc>August 31, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2010</study_first_posted>
  <results_first_submitted>May 16, 2014</results_first_submitted>
  <results_first_submitted_qc>May 16, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 17, 2014</results_first_posted>
  <last_update_submitted>May 16, 2014</last_update_submitted>
  <last_update_submitted_qc>May 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo/Empa 10mg</title>
          <description>It is actually placebo once daily group in the 12-week first treatment period, and placebo/empagliflozin 10 mg once daily group in the 40-week second treatment period</description>
        </group>
        <group group_id="P2">
          <title>Placebo/Empa 25 mg</title>
          <description>It is actually N/A in the 12-week first treatment period, and placebo/empagliflozin 25 mg once daily group in the 40-week second treatment period</description>
        </group>
        <group group_id="P3">
          <title>Empa 5mg/10mg</title>
          <description>It is actually empagliflozin 5 mg once daily group in the 12-week first treatment period, and empagliflozin 5 mg/25 mg once daily group in the 40-week second treatment period</description>
        </group>
        <group group_id="P4">
          <title>Empa 5 mg/25 mg</title>
          <description>It is actually N/A in the 12-week first treatment period, and empagliflozin 5 mg/25 mg once daily group in the 40-week second treatment period</description>
        </group>
        <group group_id="P5">
          <title>Empa 10mg</title>
          <description>Empagliflozin 10 mg once daily group both in the 12-week first treatment period and the 40-week second treatment period</description>
        </group>
        <group group_id="P6">
          <title>Empa 25mg</title>
          <description>Empagliflozin 25 mg once daily group both in the 12-week first treatment period and the 40-week second treatment period</description>
        </group>
        <group group_id="P7">
          <title>Empa 50mg\10mg</title>
          <description>It is actually empagliflozin 50 mg once daily group in the 12-week first treatment period, and empagliflozin 50 mg/10 mg once daily group in the 40-week second treatment period</description>
        </group>
        <group group_id="P8">
          <title>Empa 50 mg/25 mg</title>
          <description>It is actually N/A in the 12-week first treatment period, and empagliflozin 50 mg/25 mg once daily group in the 40-week second treatment period</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>0-12 Weeks</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="109">It is actually placebo group</participants>
                <participants group_id="P2" count="0">It is actually N/A</participants>
                <participants group_id="P3" count="110">It is actually empa 5mg group</participants>
                <participants group_id="P4" count="0">It is actually N/A</participants>
                <participants group_id="P5" count="109"/>
                <participants group_id="P6" count="109"/>
                <participants group_id="P7" count="110">It is actually empa 50mg group</participants>
                <participants group_id="P8" count="0">It is actually N/A</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="107"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="108"/>
                <participants group_id="P6" count="106"/>
                <participants group_id="P7" count="107"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>12-52 Weeks</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="50"/>
                <participants group_id="P3" count="54"/>
                <participants group_id="P4" count="53"/>
                <participants group_id="P5" count="108"/>
                <participants group_id="P6" count="106"/>
                <participants group_id="P7" count="54"/>
                <participants group_id="P8" count="53"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="50"/>
                <participants group_id="P3" count="50"/>
                <participants group_id="P4" count="50"/>
                <participants group_id="P5" count="104"/>
                <participants group_id="P6" count="101"/>
                <participants group_id="P7" count="51"/>
                <participants group_id="P8" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reason than above</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo (12 Week)</title>
          <description>Placebo once daily group in the 12-week first treatment period</description>
        </group>
        <group group_id="B2">
          <title>Empa 5mg (12 Week)</title>
          <description>Empagliflozin 5 mg once daily group in the 12-week first treatment period</description>
        </group>
        <group group_id="B3">
          <title>Empa 10mg (12 Week)</title>
          <description>Empagliflozin 10 mg once daily group in the 12-week first treatment period</description>
        </group>
        <group group_id="B4">
          <title>Empa 25mg (12 Week)</title>
          <description>Empagliflozin 25 mg once daily group in the 12-week first treatment period</description>
        </group>
        <group group_id="B5">
          <title>Empa 50mg (12 Week)</title>
          <description>Empagliflozin 50 mg once daily group in the 12-week first treatment period</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="109"/>
            <count group_id="B2" value="110"/>
            <count group_id="B3" value="109"/>
            <count group_id="B4" value="109"/>
            <count group_id="B5" value="110"/>
            <count group_id="B6" value="547"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.7" spread="8.7"/>
                    <measurement group_id="B2" value="57.3" spread="11.2"/>
                    <measurement group_id="B3" value="57.9" spread="9.4"/>
                    <measurement group_id="B4" value="57.2" spread="9.7"/>
                    <measurement group_id="B5" value="56.6" spread="10.3"/>
                    <measurement group_id="B6" value="57.5" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="25"/>
                    <measurement group_id="B6" value="137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="77"/>
                    <measurement group_id="B4" value="84"/>
                    <measurement group_id="B5" value="85"/>
                    <measurement group_id="B6" value="410"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in HbA1c After 12 Weeks of Treatment.</title>
        <description>The primary endpoint in this study is the change from baseline in HbA1c after 12 weeks of treatment.</description>
        <time_frame>baseline and 12 weeks</time_frame>
        <population>Full analysis set (FAS)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (12 Week)</title>
            <description>Placebo once daily group in the 12-week first treatment period</description>
          </group>
          <group group_id="O2">
            <title>Empa 5mg (12 Week)</title>
            <description>Empagliflozin 5 mg once daily group in the 12-week first treatment period</description>
          </group>
          <group group_id="O3">
            <title>Empa 10mg (12 Week)</title>
            <description>Empagliflozin 10 mg once daily group in the 12-week first treatment period</description>
          </group>
          <group group_id="O4">
            <title>Empa 25mg (12 Week)</title>
            <description>Empagliflozin 25 mg once daily group in the 12-week first treatment period</description>
          </group>
          <group group_id="O5">
            <title>Empa 50mg (12 Week)</title>
            <description>Empagliflozin 50 mg once daily group in the 12-week first treatment period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HbA1c After 12 Weeks of Treatment.</title>
          <description>The primary endpoint in this study is the change from baseline in HbA1c after 12 weeks of treatment.</description>
          <population>Full analysis set (FAS)</population>
          <units>percentage of HbA1c</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="110"/>
                <count group_id="O3" value="109"/>
                <count group_id="O4" value="109"/>
                <count group_id="O5" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.30" spread="0.09"/>
                    <measurement group_id="O2" value="-0.42" spread="0.09"/>
                    <measurement group_id="O3" value="-0.40" spread="0.09"/>
                    <measurement group_id="O4" value="-0.65" spread="0.09"/>
                    <measurement group_id="O5" value="-0.61" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference calculated as empa 5mg minus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>the analyses were made sequentially compared with placebo from high dose of empagliflozin and the full significant level (5%) was maintained by the hierarchical procedure.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>‘treatment’, ‘renal function’, and ‘number of previous antidiabetic medication’ as a fixed effect and baseline HbA1c as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.72</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.08</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.87</ci_lower_limit>
            <ci_upper_limit>-0.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Difference calculated as empa 10mg minus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>the analyses were made sequentially compared with placebo from high dose of empagliflozin and the full significant level (5%) was maintained by the hierarchical procedure.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>‘treatment’, ‘renal function’, and ‘number of previous antidiabetic medication’ as a fixed effect and baseline HbA1c as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.70</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.08</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.85</ci_lower_limit>
            <ci_upper_limit>-0.55</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Difference calculated as empa 25mg minus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>the analyses were made sequentially compared with placebo from high dose of empagliflozin and the full significant level (5%) was maintained by the hierarchical procedure.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>‘treatment’, ‘renal function’, and ‘number of previous antidiabetic medication’ as a fixed effect and baseline HbA1c as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.95</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.08</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.10</ci_lower_limit>
            <ci_upper_limit>-0.80</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference calculated as empa 50mg minus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>the analyses were made sequentially compared with placebo from high dose of empagliflozin and the full significant level (5%) was maintained by the hierarchical procedure.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>‘treatment’, ‘renal function’, and ‘number of previous antidiabetic medication’ as a fixed effect and baseline HbA1c as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.91</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.08</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.06</ci_lower_limit>
            <ci_upper_limit>-0.76</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrence of Treat to Target Efficacy Response</title>
        <description>Occurrence of treat to target efficacy response, that is an HbA1c of &lt;7.0% after 12 weeks of treatment</description>
        <time_frame>baseline and 12 weeks</time_frame>
        <population>Full analysis set (FAS)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (12 Week)</title>
            <description>Placebo once daily group in the 12-week first treatment period</description>
          </group>
          <group group_id="O2">
            <title>Empa 5mg (12 Week)</title>
            <description>Empagliflozin 5 mg once daily group in the 12-week first treatment period</description>
          </group>
          <group group_id="O3">
            <title>Empa 10mg (12 Week)</title>
            <description>Empagliflozin 10 mg once daily group in the 12-week first treatment period</description>
          </group>
          <group group_id="O4">
            <title>Empa 25mg (12 Week)</title>
            <description>Empagliflozin 25 mg once daily group in the 12-week first treatment period</description>
          </group>
          <group group_id="O5">
            <title>Empa 50mg (12 Week)</title>
            <description>Empagliflozin 50 mg once daily group in the 12-week first treatment period</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Treat to Target Efficacy Response</title>
          <description>Occurrence of treat to target efficacy response, that is an HbA1c of &lt;7.0% after 12 weeks of treatment</description>
          <population>Full analysis set (FAS)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="107"/>
                <count group_id="O3" value="105"/>
                <count group_id="O4" value="106"/>
                <count group_id="O5" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" lower_limit="0.6" upper_limit="8.0"/>
                    <measurement group_id="O2" value="26.2" lower_limit="18.1" upper_limit="35.6"/>
                    <measurement group_id="O3" value="19.0" lower_limit="12.0" upper_limit="27.9"/>
                    <measurement group_id="O4" value="32.1" lower_limit="23.3" upper_limit="41.8"/>
                    <measurement group_id="O5" value="32.7" lower_limit="24.0" upper_limit="42.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Odds ratio calculated as the odds of Empa 5mg divided by the odds of placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>The model includes ‘treatment’, ‘renal function’, ‘number of previous antidiabetic medications’ and ‘continuous baseline HbA1c’.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>19.367</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.340</ci_lower_limit>
            <ci_upper_limit>70.236</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Odds ratio calculated as the odds of Empa 10mg divided by the odds of placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>Regression, Logistic</method>
            <method_desc>The model includes ‘treatment’, ‘renal function’, ‘number of previous antidiabetic medications’ and ‘continuous baseline HbA1c’.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>10.889</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.942</ci_lower_limit>
            <ci_upper_limit>40.301</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Odds ratio calculated as the odds of Empa 25mg divided by the odds of placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>The model includes ‘treatment’, ‘renal function’, ‘number of previous antidiabetic medications’ and ‘continuous baseline HbA1c’.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>27.624</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.601</ci_lower_limit>
            <ci_upper_limit>99.99</ci_upper_limit>
            <estimate_desc>The upper limit of confidence interval is actually &gt;99.99</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Odds ratio calculated as the odds of Empa 50mg divided by the odds of placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>The model includes ‘treatment’, ‘renal function’, ‘number of previous antidiabetic medications’ and ‘continuous baseline HbA1c’.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>44.906</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>12.120</ci_lower_limit>
            <ci_upper_limit>99.99</ci_upper_limit>
            <estimate_desc>The upper limit of confidence interval is actually &gt;99.99</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in FPG</title>
        <description>Change from baseline in FPG after 12 weeks of treatment</description>
        <time_frame>baseline and 12 weeks</time_frame>
        <population>Full analysis set (FAS)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (12 Week)</title>
            <description>Placebo once daily group in the 12-week first treatment period</description>
          </group>
          <group group_id="O2">
            <title>Empa 5mg (12 Week)</title>
            <description>Empagliflozin 5 mg once daily group in the 12-week first treatment period</description>
          </group>
          <group group_id="O3">
            <title>Empa 10mg (12 Week)</title>
            <description>Empagliflozin 10 mg once daily group in the 12-week first treatment period</description>
          </group>
          <group group_id="O4">
            <title>Empa 25mg (12 Week)</title>
            <description>Empagliflozin 25 mg once daily group in the 12-week first treatment period</description>
          </group>
          <group group_id="O5">
            <title>Empa 50mg (12 Week)</title>
            <description>Empagliflozin 50 mg once daily group in the 12-week first treatment period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in FPG</title>
          <description>Change from baseline in FPG after 12 weeks of treatment</description>
          <population>Full analysis set (FAS)</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="110"/>
                <count group_id="O3" value="109"/>
                <count group_id="O4" value="109"/>
                <count group_id="O5" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.06" spread="2.88"/>
                    <measurement group_id="O2" value="-22.65" spread="2.97"/>
                    <measurement group_id="O3" value="-25.28" spread="2.77"/>
                    <measurement group_id="O4" value="-33.70" spread="2.92"/>
                    <measurement group_id="O5" value="-32.54" spread="2.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference calculated as empa 5mg minus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>treatment, renal function, number of previous antidiabetic medication as fixed effects, baseline fasting plasma glucose, baseline HbA1c as covariates</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-26.70</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.50</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-31.61</ci_lower_limit>
            <ci_upper_limit>-21.80</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Difference calculated as empa 10mg minus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>treatment, renal function, number of previous antidiabetic medication as fixed effects, baseline fasting plasma glucose, baseline HbA1c as covariates</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-29.34</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.50</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-34.25</ci_lower_limit>
            <ci_upper_limit>-24.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Difference calculated as empa 25mg minus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>treatment, renal function, number of previous antidiabetic medication as fixed effects, baseline fasting plasma glucose, baseline HbA1c as covariates</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-37.75</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.50</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-42.66</ci_lower_limit>
            <ci_upper_limit>-32.84</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference calculated as empa 50mg minus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>treatment, renal function, number of previous antidiabetic medication as fixed effects, baseline fasting plasma glucose, baseline HbA1c as covariates</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-36.60</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.50</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-41.51</ci_lower_limit>
            <ci_upper_limit>-31.69</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Confirmed Hypoglycaemic Adverse Events</title>
        <description>Number of patients with confirmed hypoglycaemic adverse events</description>
        <time_frame>between first drug intake of study medication up to a period of 7 days (inclusive) after the last drug intake of study medication, up to 392 days</time_frame>
        <population>Treated patients</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (12 Week)</title>
            <description>Placebo once daily group in the 12-week first treatment period</description>
          </group>
          <group group_id="O2">
            <title>Empa 5mg (12 Week)</title>
            <description>Empagliflozin 5 mg once daily group in the 12-week first treatment period</description>
          </group>
          <group group_id="O3">
            <title>Empa 10mg (12 Week)</title>
            <description>Empagliflozin 10 mg once daily group in the 12-week first treatment period</description>
          </group>
          <group group_id="O4">
            <title>Empa 25mg (12 Week)</title>
            <description>Empagliflozin 25 mg once daily group in the 12-week first treatment period</description>
          </group>
          <group group_id="O5">
            <title>Empa 50mg (12 Week)</title>
            <description>Empagliflozin 50 mg once daily group in the 12-week first treatment period</description>
          </group>
        </group_list>
        <measure>
          <title>Confirmed Hypoglycaemic Adverse Events</title>
          <description>Number of patients with confirmed hypoglycaemic adverse events</description>
          <population>Treated patients</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="110"/>
                <count group_id="O3" value="109"/>
                <count group_id="O4" value="109"/>
                <count group_id="O5" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>between first drug intake of study medication up to a period of 7 days (inclusive) after the last drug intake of study medication, up to 392 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo (12 Week)</title>
          <description>Placebo once daily group in the 12-week first treatment period</description>
        </group>
        <group group_id="E2">
          <title>Empa 5mg (12 Week)</title>
          <description>Empagliflozin 5 mg once daily group in the 12-week first treatment period</description>
        </group>
        <group group_id="E3">
          <title>Empa 10mg (12 Week)</title>
          <description>Empagliflozin 10 mg once daily group in the 12-week first treatment period</description>
        </group>
        <group group_id="E4">
          <title>Empa 25mg (12 Week)</title>
          <description>Empagliflozin 25 mg once daily group in the 12-week first treatment period</description>
        </group>
        <group group_id="E5">
          <title>Empa 50mg (12 Week)</title>
          <description>Empagliflozin 50 mg once daily group in the 12-week first treatment period</description>
        </group>
        <group group_id="E6">
          <title>Empa 10mg (Randomized, 52 Week)</title>
          <description>Patients randomized to empagliflozin 10mg once daily for 52 weeks</description>
        </group>
        <group group_id="E7">
          <title>Empa 25mg (Randomized, 52 Week)</title>
          <description>Patients randomized to empagliflozin 25 mg once daily for 52 weeks</description>
        </group>
        <group group_id="E8">
          <title>Empa 10mg (With at Least One Dose, 52 Week)</title>
          <description>Patients with at least one dose of empagliflozin 10 mg once daily for 52−week treatment</description>
        </group>
        <group group_id="E9">
          <title>Empa 25mg (With at Least One Dose, 52 Week)</title>
          <description>Patients with at least one dose of empagliflozin 25 mg once daily for 52−week treatment</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MEDDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="109"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="15" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Left ventricular hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Sudden hearing loss</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Macular hole</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Carbohydrate antigen 19-9 increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Prostatic specific antigen increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Diffuse large B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Metastases to bone marrow</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="109"/>
                <counts group_id="E5" subjects_affected="20" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="39" subjects_at_risk="109"/>
                <counts group_id="E7" subjects_affected="49" subjects_at_risk="109"/>
                <counts group_id="E8" subjects_affected="83" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="93" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="109"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="109"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="10" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="109"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="9" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="109"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="30" subjects_at_risk="109"/>
                <counts group_id="E7" subjects_affected="33" subjects_at_risk="109"/>
                <counts group_id="E8" subjects_affected="62" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="63" subjects_at_risk="265"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="109"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="109"/>
                <counts group_id="E8" subjects_affected="11" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="9" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="109"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="109"/>
                <counts group_id="E8" subjects_affected="14" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="10" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="109"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="110"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="109"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="267"/>
                <counts group_id="E9" subjects_affected="10" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

